Social Behavior
Sanofi’s Strategic Acquisition of Principia Bears Fruit with Rilzabrutinib’s Phase III Success
Sanofi, Principia, acquisition, Rilzabrutinib, Phase III, clinical trial, success, strategic investment, pharmaceutical industry, biotechnology, drug development.
Boehringer Ingelheim and Ochre Bio Join Forces in a $1 Billion Collaboration to Combat Chronic Liver Diseases
Boehringer Ingelheim, Ochre Bio, collaboration, chronic liver diseases, $1 billion, drug discovery, RNA therapeutics, liver fibrosis, non-alcoholic steatohepatitis (NASH)
CSL Vifor’s Corrective Marketing Initiative to Address Anti-Competitive Concerns
CSL Vifor, marketing campaign, anti-competitive practices, competition law, corrective measures, pharmaceutical industry, competition watchdog, market fairness.
CSL Vifor Proposes Corrective Campaign to Resolve EU Antitrust Probe
CSL Vifor, EU Antitrust Probe, Corrective Campaign, Multi-Channel Communication, Competition
Director/Vice President of Translational Research: Leading the Bridge from Discovery to Clinical Development
Translational Research, Biomarker Discovery, Preclinical Development, Early Clinical Development, Drug Molecule Development, Translational Science Leadership, Biomarker Development, Target Engagement Strategies, Assay Development (PK/ PD/ Immunogenicity), Clinical Trial Design, Endpoint and Biomarker Strategy, Team Building and Leadership, Cross-Functional Collaboration, Regulatory Approvals
FDA Launches CDER Center for Clinical Trial Innovation (C3TI) to Boost Trial Design and Efficiency
FDA, CDER (Center for Drug Evaluation and Research), C3TI (CDER Center for Clinical Trial Innovation), Clinical trial innovation, Efficiency, Drug development, Trial design, Collaboration
European Commission Grants Approval for Illumina to Divest Grail
Illumina, Grail, European Commission, Divestment, Competition, Antitrust
FDA Approves BrainStorm’s Phase IIIb Trial Design for NurOwn in Early-Stage ALS
BrainStorm Cell Therapeutics, NurOwn, Phase IIIb trial, Special Protocol Assessment (SPA), FDA agreement, Early-stage ALS, Amyotrophic Lateral Sclerosis (ALS)
Enhanced Optimization for Influenza B Strains Planned in CureVac’s mRNA Seasonal Flu Vaccine Trials
CureVac, mRNA flu vaccine, Influenza B strains, Targeted optimization, Phase 2 studies, Multivalent candidate, Improved immune response, Collaboration with GSK
Genmab Acquires ProfoundBio for $1.8 Billion to Challenge AbbVie’s Elahere in ADC Market
Genmab, ProfoundBio, $1.8 billion acquisition, Antibody Drug Conjugates (ADCs), Competition with AbbVie’s Elahere, Rinatabart sesutecan (Rina-S), Folate Receptor Alpha (FRα), Midphase clinical trials